Skye Bioscience Inc (SKYE) News

Form 8-K - Current report

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form S-3 - Registration statement under Securities Act of 1933

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Marshall Edwards Announces Additional Management Changes With Appointment of New Chief Financial Officer

SAN DIEGO, CA -- (Marketwire) -- 06/17/10 -- Marshall Edwards, Inc. (NASDAQ: MSHL), an oncology company focused on the clinical development of...

SkyePharma PLC announces Final Results

London, UK -- (Marketwire) -- 03/25/10 -- Preliminary statement of annual results SkyePharma PLC (LSE: SKP), LONDON, ENGLAND, 25 March...

Skyepharma PLC announces - Regulatory Update

London, UK -- (Marketwire) -- 01/21/10 -- SKYEPHARMA PLC - FlutiformTM U.S. NDA Update LONDON, UK, 21 January 2010 - SkyePharma PLC (LSE: SKP...

Skyepharma PLC - Board Change

LONDON -- (Marketwire) -- 11/18/09 -- SKYEPHARMA PLC - BOARD CHANGE - CHAIRMAN LONDON, UK, 18 November, 2009 - SkyePharma PLC (LSE: SKP...

Skyepharma PLC - Interim Management Statement

LONDON -- (Marketwire) -- 11/12/09 -- SKYEPHARMA PLC - INTERIM MANAGEMENT STATEMENT LONDON, UK, 12 November - SkyePharma PLC (LSE: SKP) today...

Flutiform EU Clinical Trial Successfully Completed

LONDON -- (Marketwire) -- 11/02/09 -- FOR IMMEDIATE RELEASE SkyePharma Announces Successful Completion of FlutiformTM EU Clinical Trial...

SKYEPHARMA PLC - Research Update

LONDON -- (Marketwire) -- 09/01/09 -- SKYEPHARMA PLC - Flutiform(TM) U.S. Filing Update LONDON, UK, 1 September 2009 - SkyePharma PLC (LSE:...

Skyepharma PLC announces Conversion of Bonds

LONDON, UK -- (Marketwire) -- 06/22/09 -- Conversion of GBP2,500,000 6% 2024 Bonds LONDON, UK, 22 June 2009 -- SkyePharma PLC (LSE: SKP) today...